HOME > BUSINESS
BUSINESS
- Otsuka Completes Acquisition of Avanir for US$3.56 Billion
January 15, 2015
- Lantus Biosimilar Approved: Eli Lilly Japan, NBI
January 15, 2015
- Takeda to Roll Out Colcrys AG in US
January 14, 2015
- Meiji, Roche, Fedora Tie Up for Development, Commercialization of Beta-Lactamase Inhibitor
January 14, 2015
- Ethical Drug Sales Down 7.6% in November: Crecon Report
January 14, 2015
- Daiichi Sankyo Reaches Settlement with US DOJ Following Investigation of Promotional Activities; to Pay US$39 Million
January 14, 2015
- GSK, Nippon Kayaku to End Copromotion of Cancer Drug Tykerb
January 13, 2015
- Otsuka, Fuso to Terminate Cancer Vaccine Deals with OncoTherapy
January 13, 2015
- FDA Approves Edoxaban for AF, VTE: Daiichi Sankyo
January 13, 2015
- GSK Japan Unit to Cut Jobs amid Global Restructuring Move
January 9, 2015
- FDA Accepts sNDA for Aptiom to Treat Partial-Onset Seizures
January 9, 2015
- Takeda Begins PII/III, PIII Studies of Rasagiline
January 9, 2015
- Kyowa Kirin Licenses Anticancer Drug from Syndax in Japan and South Korea
January 9, 2015
- Leading Generic Makers Disclose FY2013 Payments to Healthcare Professionals
January 8, 2015
- Celgene Applies for Additional Indication of Untreated Multiple Myeloma for Revlimid
January 8, 2015
- Hospira’s Oxaliplatin Generics Approved for Unresectable Pancreatic Cancer
January 8, 2015
- Takeda’s Potassium-Competitive Acid Blocker Approved in Japan
January 7, 2015
- Perampanel Meets Primary Endpoint in PIII Study for Asian Patients: Eisai
January 7, 2015
- Janssen Obtains Approval of Anti-HIV Drug Prezista Tablets 600 mg
January 7, 2015
- Taiho Obtains Approval of Double-Bag Formulation of Zosyn
January 7, 2015
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…